What changed
$WST — AVOID 📊
West Pharmaceutical Services, Inc.
🎯 Q2 2026 | Rev $1B | EPS $2.13 vs $1.68 🟢
💡 Consensus likely expected a weak quarter, but the beat is already priced in. The market's high PE implies growth expectations that are vulnerable to any disappointment, while quantitative models rank the stock at the bottom of its sector and universe, pointing to -0.0% expected return.
📉 Reward/Risk: 0.67:1
🏢 Business Quality: 6/10 - limited information; high PE suggests market perceives quality, but no details on margins, moat, or growth were provided, and factor rank is among the worst.
📊 Valuation: rich - PE 44.5x, at historical median (no range), absolutely elevated; no other multiples available for triangulation, but 44.5x is expensive versus...
📊 Our read: AVOID. Full analysis →
https://stockduty.xyz/s/WST0623
Also in play: $WAB $GBX $TRN $CAT $DE $NSC